These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Experiences with the realisation of innovative study designs using the example of the HOPE-study]. Rangoonwala B Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S82-5. PubMed ID: 15988674 [No Abstract] [Full Text] [Related]
3. The renin angiotensin system and cardiovascular disease: hope or hype? Williams B J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):142-6. PubMed ID: 11967805 [No Abstract] [Full Text] [Related]
4. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection? Ong HT J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698 [TBL] [Abstract][Full Text] [Related]
5. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634 [TBL] [Abstract][Full Text] [Related]
6. ACE inhibitors and cardiovascular protection in diabetes. Donnelly R Diabetes Obes Metab; 2004 Nov; 6(6):399-401. PubMed ID: 15479215 [No Abstract] [Full Text] [Related]
7. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Gerstein HC Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991 [TBL] [Abstract][Full Text] [Related]
8. [Ramipril and new therapeutic possibilities for ACE-inhibitors]. Vespasiani Gentilucci U; Picardi A Clin Ter; 2000; 151(4):307-8. PubMed ID: 11107682 [No Abstract] [Full Text] [Related]
9. Reducing complications in type 2 diabetes. Poirier SJ Am Fam Physician; 1998 Mar; 57(6):1238-9. PubMed ID: 9531907 [No Abstract] [Full Text] [Related]
11. Current indications for ACE inhibitors and HOPE for the future. Burch S; Ou N Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599 [TBL] [Abstract][Full Text] [Related]
12. What is the relevance of the HOPE study in general practice? Kennedy J; Mogensen CE; Ball SG; Castaigne AD; Commerford PJ; Distiller L; Fisher BM; Gonzalez-Jaunatey J; Nosadini R; Novials A; Ostergren J; Palma-Gámiz J; Perrone-Filardi P; Schipperheijn JJ; Senges J; Trevisan R Int J Clin Pract; 2001 Sep; 55(7):449-57. PubMed ID: 11594254 [TBL] [Abstract][Full Text] [Related]
13. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases]. Ferrari R; Ambrosio G; Chiariello M Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511 [No Abstract] [Full Text] [Related]
14. The HOPE Study (Heart Outcomes Prevention Evaluation). Sleight P J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789 [TBL] [Abstract][Full Text] [Related]
15. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice]. Pocanić D Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282 [TBL] [Abstract][Full Text] [Related]
17. [Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005]. Traut V Dtsch Med Wochenschr; 2005 Nov; 130(47):2726; author reply 2727-8. PubMed ID: 16294292 [No Abstract] [Full Text] [Related]
18. Inhibition of the renin-angiotensin system in cardiovascular protection: Is it important to watch your C'ARB' intake? Strauss MH; Verma S Can J Cardiol; 2005 May; 21(7):577-80. PubMed ID: 15940355 [No Abstract] [Full Text] [Related]